Drug Trial Radar · NCT03989206
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis
Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,935
Actual
Start
Dec 30, 2019
Primary completion
Aug 31, 2026
Study completion Aug 31, 2026
Sponsor
- Lead sponsor
- Galderma R&DIndustry
- Sponsor type
- Industry
- First posted
- Jun 18, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description
Conditions
- Moderate-to-Severe Atopic Dermatitis
Interventions
NemolizumabDrug
Nemolizumab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and Severity of TEAEsTime frame: Baseline to Week 200
- Incidence of Serious TEAEsTime frame: Baseline to Week 200
- Incidence and Severity of Adverse Events of Special Interest (AESIs) Throughout the StudyTime frame: Baseline to Week 200
Locations
343 sites in 22 countries. Site status is shown where the registry gives one.
Galderma Investigational Site 8749
Birmingham, Alabama
Galderma Investigational Site 8893
Birmingham, Alabama
Galderma Investigational Site 8866
Guntersville, Alabama
Galderma Investigational Site 8808
Scottsdale, Arizona
Galderma Investigational Site 8873
Scottsdale, Arizona
Galderma Investigational Site 8447
Fort Smith, Arkansas
Galderma Investigational Site 8880
North Little Rock, Arkansas
Galderma Investigational Site 8831
Anaheim, California
Galderma Investigational Site 8906
Bell Gardens, California
Galderma Investigational Site 8456
Beverly Hills, California
Galderma Investigational Site 8578
Cerritos, California
Galderma Investigational Site 8577
Encinitas, California
Galderma Investigational Site 8636
Fountain Valley, California
Galderma Investigational Site 8224
Fremont, California
Galderma Investigational Site 8791
Fresno, California
Galderma Investigational Site 8888
Fullerton, California
Galderma Investigational Site 8845
Huntington Beach, California
Galderma Investigational Site 8833
Inglewood, California
Galderma Investigational Site 8686
Lomita, California
Galderma Investigational Site 8674
Los Angeles, California
Galderma Investigational Site 8683
Los Angeles, California
Galderma Investigational Site 8813
Los Angeles, California
Galderma Investigational Site 8907
Newport Beach, California
Galderma Investigational Site 8799
Ontario, California
Galderma Investigational Site 8745
Pasadena, California
Galderma Investigational Site 8671
San Diego, California
Galderma Investigational Site 8692
San Diego, California
Galderma Investigational Site 8658
San Diego, California
Galderma Investigational Site 8125
San Francisco, California
Galderma Investigational Site 8536
Santa Ana, California
Galderma Investigational Site 8608
Santa Monica, California
Galderma Investigational Site 8820
Westminster, California
Galderma Investigational Site 8637
Farmington, Connecticut
Galderma Investigational Site 8870
Boca Raton, Florida
Galderma Investigational Site 8805
Cape Coral, Florida
Galderma Investigational Site 8786
Clearwater, Florida
Galderma Investigational Site 8902
Doral, Florida
Galderma Investigational Site 8391
Hialeah, Florida
Galderma Investigational Site 8804
Hialeah, Florida
Galderma Investigational Site 8711
Jacksonville, Florida
Showing 40 of 343 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.